ISB 1442 antibody therapy wins US orphan drug status
ISB 1442, Ichnos Sciences’Â investigational bi-specific antibody-based treatment, has earned orphan drug designation from the U.S. Food and Drug Administration (FDA) for treating relapsed or…
Lindsey Shapiro, PhD, science writer — 
Articles by Lindsey Shapiro
EasyM, blood test for residual myeloma activity, certified in US
Multiple myeloma patients in the U.S. will now have access to Rapid Novor‘s noninvasive and highly sensitive blood test for monitoring minimal residual…
IASO Biotherapeutics’ CAR T-cell therapy gets fresh FDA support
The U.S. Food and Drug Administration (FDA) has granted fast track and regenerative medicine advanced therapy designations to CT103A, IASO Biotherapeutics’ experimental CAR T-cell therapy…
Worse Prognosis Found for Obese, Underweight Myeloma Patients
Extremes in body mass index (BMI) — a ratio of weight to height that’s used to estimate a person’s healthy weight — are associated with…
Data: Revlimid Triple Combo Is Better as Myeloma Maintenance Therapy
In people with newly diagnosed multiple myeloma following a stem cell transplant, a triple-combination maintenance therapy — of Revlimid (lenalidomide), Kyprolis (carfilzomib)…
MCARH109, CAR T-cell Therapy for Advanced MM, Shows Potential
A new investigational CAR T-cell therapy, called MCARH109, demonstrated an ability to shrink or eliminate the amount of cancer in patients with relapsed or refractory…
Trial to Test Abecma in Patients With Poor Stem Cell Transplant Response
An upcoming clinical trial will evaluate the CAR T-cell therapy Abecma (idecabtagene vicleucel) in people newly diagnosed with multiple myeloma who had a…
Myeloma Action Month Reaches More Than 30M Worldwide, Foundation Says
More than 30 million people in 46 countries joined together to participate in Myeloma Action Month (MAM), a campaign in March to raise awareness…
IMF Opening ‘Action’ Campaign to Mark Myeloma Awareness Month
The International Myeloma Foundation (IMF) is opening its annual Myeloma Action Month (MAM) campaign with a variety of events and undertakings…